Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V540D vs GARDASIL®9 in Healthy Adults
NCT06688058Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V540D in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE) at 26 weeks, Number of Participants Who Experience a Solicited Systemic AE at 26 weeks and 5 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
V540D
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06688058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688058.